期刊文献+

心房颤动影响因素的非匹配病例对照研究 被引量:3

A non-matching case-control study of influence factors for atrial fibrillation
下载PDF
导出
摘要 目的分析心房颤动患者的影响因素,为制定相关干预措施提供科学依据。方法选取住院治疗资料完整的心房颤动患者作为病例组,并随机从同时期在心内科接受治疗的其他非心房颤动患者中选取同等数量作为对照组进行非匹配的病例对照研究,采用多因素非条件logistic回归方法分析心房颤动的影响因素。结果共有效调查556例患者,其中病例组和对照组分别为278例。多因素分析结果显示,年龄增加(OR=1.037,95%CI:1.022~1.052)、高血压(OR=2.395,95%CI:1.361~4.214)、糖尿病(OR=2.374,95%CI:1.301~4.333)、冠心病(OR=2.620,95%CI:1.480~4.638)、心脏病(OR=3.468,95%CI:1.834~6.560)、心力衰竭(OR=3.050,95%CI:1.741~5.345)、尿酸增加(OR=1.011,95%CI:1.005~1.016)、左房内径增加(OR=1.201,95%CI:1.130~1.276)是房颤的危险因素;女性(OR=0.518,95%CI:0.321~0.837)、左室射血分数(OR=0.097,95%CI:0.021~0.449)、三酰甘油(OR=0.418,95%CI:0.252~0.693)、高密度脂蛋白(OR=0.381,95%CI:0.213~0.683)以及低密度脂蛋白水平增加(OR=0.230,95%CI:0.127~0.417)是房颤的保护因素。结论很多因素可以影响心房颤动的发生,相关部门应该从多方面制定综合的心房颤动预防控制措施。 Objective To investigate the influence factors of atrial fibrillation to provide a scientific basis for the government to make the intervention measures. Methods The patients of atrial fibrillation who had complete information and were hospitalized in department of cardiology of Lu’an People’s Hospital from January to May,2014 were viewed as case group. The other patients who did not have atrial fibrillation and were hospitalized in department of cardiology in the same period were randomly selected as the control group. The non-matching casecontrol study and unconditioned multivariate logistic regression were used to analyze the relative factors of atrial fibrillation. Results A total of 556 participants( number of case group and control group was 278,278,respectively) were included in this analysis. The elder age( OR =1. 037,95% CI: 1. 022 ~ 1. 052),hypertension( OR = 2. 395,95% CI: 1. 361 ~ 4. 214),diabetes( OR = 2. 374,95% CI: 1. 301 ~ 4. 333),coronary heart disease( OR = 2. 620,95% CI: 1. 480 ~ 4. 638),heart disease( OR = 3. 468,95% CI: 1. 834 ~ 6. 560),heart failure( OR =3. 050,95% CI: 1. 741 ~ 5. 345),increased uric acid( OR = 1. 011,95% CI: 1. 005 ~ 1. 016),and increased left atrial diameter( OR =1. 201,95% CI: 1. 130 ~ 1. 276) were risk factors for atrial fibrillation; women( OR = 0. 518,95% CI: 0. 321 ~ 0. 837),an increased level of left ventricular ejection fraction( OR = 0. 097,95% CI: 0. 021 ~ 0. 449),triglycerides( OR = 0. 418,95% CI: 0. 252 ~ 0. 693),high density lipoprotein( OR = 0. 381,95% CI: 0. 213 ~ 0. 683) and low density lipoprotein( OR = 0. 230,95% CI: 0. 127 ~ 0. 417) were the protective factors for atrial fibrillation. Conclusion Many factors can affect the atrial fibrillation,therefore,relevant departments should make comprehensive intervention measures for atrial fibrillation.
出处 《安徽医学》 2015年第1期45-48,共4页 Anhui Medical Journal
关键词 心房颤动 影响因素 非匹配 病例对照研究 Atrial fibrillation Influence factor Non-matching Case-control study
  • 相关文献

参考文献17

二级参考文献163

共引文献1484

同被引文献30

  • 1MUNGER T M, WU L Q, SHEN W K. Atrial fibrillation [ J]. J Biomed Res, 2014, 28 ( 1 ) : 1 17. DOI: 10. 7555/JBR. 28. 20130191. 被引量:1
  • 2BUNCH T J, MAY H T, BAIR T L, et al. Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes [J]. Heart Rhythm, 2013, 10 (9) : 1257 - 1262. DOI: 10. 1016/j. hrthm. 2013.05. 013. 被引量:1
  • 3SPINLER S A, SHAFIR V. New oral anticoagulants for atrial fibrillation [J]. Circulation, 2012, 126 ( 1 ) : 133 - 137. DOI: 10. 1161/CIRCULATIONAHA. 112. 099283. 被引量:1
  • 4CALKINS H, KUCK K H, CAPPATO R, et al. 2012 HRS/EHRA/ ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow - up, definitions, endpoints, and research trial design [J]. Europace, 2012, 14 (4) : 528 -606. DOI: 10. 1093/europace/eus027. 被引量:1
  • 5CAPPATO R, CALKINS H, CHEN S A, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation [J]. Cire Arrhythm Electrophysiol, 2010, 3 (1) : 32 -38. DOI: 10. ll61/CIRCEP. 109. 859116. 被引量:1
  • 6CALKINS H, BRUGADA J, PACKER D L, et al. HRS/EHRA/ ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation : recommendations for personnel, policy, procedures and follow-up [J]. Europaee, 2007, 4 (9): 335 -379. DOI: 10. 1093/europace/eum120. 被引量:1
  • 7SNIPELISKY D, KUSUMOTO F. Current strategies to minimize the bleeding risk of warfarin [J]. J Blood Med, 2013, 4 (4) : 89 - 99. DOI: 10. 2147/JBM. $41404. 被引量:1
  • 8KNIGHT B P. Anticoagulation for atrial fibrillation ablation: what is the optimal strategy [ J]. J Am Coil Cardiol, 2012, 59 (13) : 1175 - 1177. DOI: 10. 1016/j. jacc. 2011.11. 044. 被引量:1
  • 9GARNOCK - JONES K P. Dabigatran etexilate : a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation [J]. Am J Cardiovasc Drugs, 2011, 11 (1) : 57 - 72. DOI: 10. 2165/11206400 -000000000 -000013. 被引量:1
  • 10BIN ABDULHAK A A, KHAN A R, TLEYJEH I M, et al. Safety and efficacy of interrupted dabigatran for peri - procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta- analysis [ J]. Europaee, 2013, 15 (10) : 1412 -1420. DOI: 10. 1093/europace/eut239. 被引量:1

引证文献3

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部